Serum interleukin-6 levels correlate with resistance to treatment of chronic hepatitis C infection with pegylated-interferon-α2b plus ribavirin

Antiviral Therapy

Volumn 16, Issue 7, 2011, Pages 1081-1091

  Ueyama, Mayumi ^a   Nakagawa, Mina ^a   Sakamoto, Naoya ^a   Onozuka, Izumi ^a   Funaoka, Yusuke ^a   Watanabe, Takako ^a   Nitta, Sayuri ^a   Kiyohashi, Kei ^a   Kitazume, Akiko ^a   Murakawa, Miyako ^a   Nishimura Sakurai, Yuki ^a   Sekine Osajima, Yuko ^a   Itsui, Yasuhiro ^b   Azuma, Seishin ^a   Kakinuma, Sei ^a   Watanabe, Mamoru ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b Soka Municipal Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DEPRESSION; DRUG DOSE REDUCTION; DRUG RESPONSE; FEMALE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; SIDE EFFECT; SKIN DISEASE; SUSTAINED VIROLOGICAL RESPONSE; THROMBOCYTE;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-6; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 80055094219     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1864     Document Type: Article

References (47)

1. Williams MJ, Lang-Lenton M. Progression of initially mild hepatic fibrosis in patients with chronic hepatitis C infection. J Viral Hepat 2011; 18:17-22.
2. Koike K. Pathogenesis of HCV-associated HCC: Dualpass carcinogenesis through activation of oxidative stress and intracellular signaling. Hepatol Res 2007; 37 Suppl 2:S115-S120.
3. Saito I, Miyamura T, Ohbayashi A, et al. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci U S A 1990; 87:6547-6549.
4. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
5. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343:1666-1672.
6. Ascione A, De Luca M, Tartaglione MT, et al. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology 2010; 138:116-122.
7. Bruno S, Shiffman ML, Roberts SK, et al. Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis. Hepatology 2010; 51:388-397.
8. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461:399-401.
9. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferonalpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41:1105-1109.
10. Enomoto N, Sakuma I, Asahina Y, et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996; 334:77-82.
11. Akuta N, Suzuki F, Sezaki H, et al. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology 2005; 48:372-380. (Pubitemid 41003622)
12. Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J 1990; 265:621-636. (Pubitemid 20053863)
13. Sehgal PB. Interleukin-6: a regulator of plasma protein gene expression in hepatic and non-hepatic tissues. Mol Biol Med 1990; 7:117-130. (Pubitemid 20198143)
14. Oyanagi Y, Takahashi T, Matsui S, et al. Enhanced expression of interleukin-6 in chronic hepatitis C. Liver 1999; 19:464-472. (Pubitemid 30019059)
15. Lee Y, Park US, Choi I, et al. Human interleukin 6 gene is activated by hepatitis B virus-X protein in human hepatoma cells. Clin Cancer Res 1998; 4:1711-1717. (Pubitemid 28304733)
16. Sheron N, Bird G, Goka J, et al. Elevated plasma interleukin-6 and increased severity and mortality in alcoholic hepatitis. Clin Exp Immunol 1991; 84:449-453.
17. van der Poorten D, Milner KL, Hui J, et al. Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. Hepatology 2008; 48:449-457.
18. Khoruts A, Stahnke L, McClain CJ, et al. Circulating tumor necrosis factor, interleukin-1 and interleukin-6 concentrations in chronic alcoholic patients. Hepatology 1991; 13:267-276.
19. Machida K, Cheng KT, Sung VM, et al. Hepatitis C virus induces toll-like receptor 4 expression, leading to enhanced production of beta interferon and interleukin-6. J Virol 2006; 80:866-874. (Pubitemid 43062898)
20. Malaguarnera M, DiFazio I, Laurino A, et al. Serum interleukin 6 concentrations in chronic hepatitis C patients before and after interferon-alpha treatment. Int J Clin Pharmacol Ther 1997; 35:385-388. (Pubitemid 27417679)
21. Naugler WE, Sakurai T, Kim S, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007; 317:121-124. (Pubitemid 47056470)
22. Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001; 286:327-334. (Pubitemid 32656163)
23. Moschen AR, Molnar C, Geiger S, et al. Anti-inflammatory effects of excessive weight loss: potent suppression of adipose interleukin 6 and tumour necrosis factor alpha expression. Gut 2010; 59:1259-1264.
24. Klover PJ, Clementi AH, Mooney RA. Interleukin-6 depletion selectively improves hepatic insulin action in obesity. Endocrinology 2005; 146:3417-3427. (Pubitemid 41058114)
25. Pietrangelo A, Dierssen U, Valli L, et al. STAT3 is required for IL-6-gp130-dependent activation of hepcidin in vivo. Gastroenterology 2007; 132:294-300. (Pubitemid 46108739)
26. Shikano M, Sobajima H, Yoshikawa H, et al. Usefulness of a highly sensitive urinary and serum IL-6 assay in patients with diabetic nephropathy. Nephron 2000; 85:81-85. (Pubitemid 30242834)
27. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004; 4:499-511. (Pubitemid 38931765)
28. Naugler WE, Karin M. The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med 2008; 14:109-119.
29. Ogata H, Kobayashi T, Chinen T, et al. Deletion of the SOCS3 gene in liver parenchymal cells promotes hepatitisinduced hepatocarcinogenesis. Gastroenterology 2006; 131:179-193. (Pubitemid 44015756)
30. Huang Y, Feld JJ, Sapp RK, et al. Defective hepatic response to interferon and activation of suppressor of cytokine signaling 3 in chronic hepatitis C. Gastroenterology 2007; 132:733-744. (Pubitemid 46274665)
31. Suda G, Sakamoto N, Itsui Y, et al. IL-6-mediated intersubgenotypic variation of interferon sensitivity in hepatitis C virus genotype 2a/2b chimeric clones. Virology 2010; 407:80-90.
32. Szabo G, Dolganiuc A, Mandrekar P. Pattern recognition receptors: a contemporary view on liver diseases. Hepatology 2006; 44:287-298. (Pubitemid 44214866)
33. Gale M, Jr., Foy EM. Evasion of intracellular host defence by hepatitis C virus. Nature 2005; 436:939-945. (Pubitemid 41191669)
34. Marra F, Bertolani C. Adipokines in liver diseases. Hepatology 2009; 50:957-969.
35. Nonogaki K, Fuller GM, Fuentes NL, et al. Interleukin-6 stimulates hepatic triglyceride secretion in rats. Endocrinology 1995; 136:2143-2149.
36. Walsh MJ, Jonsson JR, Richardson MM, et al. Nonresponse to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut 2006; 55:529-535.
37. Mochizuki K, Misaki Y, Miyauchi R, et al. Circulating interleukin-1beta and interleukin-6 concentrations are closely associated with gamma-glutamyltranspeptidase activity in middle-aged Japanese men without obvious cardiovascular diseases. Metabolism 2011; 60:914-922.
38. Lonardo A, Lombardini S, Scaglioni F, et al. Hepatic steatosis and insulin resistance: does etiology make a difference? J Hepatol 2006; 44:190-196. (Pubitemid 41772534)
39. Villela-Nogueira CA, Perez RM, de Segadas Soares JA, Coelho HS. Gamma-glutamyl transferase (GGT) as an independent predictive factor of sustained virologic response in patients with hepatitis C treated with interferon-alpha and ribavirin. J Clin Gastroenterol 2005; 39:728-730. (Pubitemid 41177095)
40. Chen L, Borozan I, Feld J, et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 2005; 128:1437-1444. (Pubitemid 40712193)
41. Fishman D, Faulds G, Jeffery R, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998; 102:1369-1376. (Pubitemid 28467565)
42. Nattermann J, Vogel M, Berg T, et al. Effect of the interleukin-6 C174G gene polymorphism on treatment of acute and chronic hepatitis C in human immunodeficiency virus coinfected patients. Hepatology 2007; 46:1016-1025. (Pubitemid 350144766)
43. Barrett S, Collins M, Kenny C, et al. Polymorphisms in tumour necrosis factor-alpha, transforming growth factorbeta, interleukin-10, interleukin-6, interferon-gamma, and outcome of hepatitis C virus infection. J Med Virol 2003; 71:212-218. (Pubitemid 37048464)
44. Di Martino V, Lebray P, Myers RP, et al. Progression of liver fibrosis in women infected with hepatitis C: long-term benefit of estrogen exposure. Hepatology 2004; 40:1426-1433. (Pubitemid 39657018)
45. Porta C, Amici M, Quaglini S, et al. Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma. Ann Oncol 2008; 19:353-358. (Pubitemid 351201719)
46. Soresi M, Giannitrapani L, D'Antona F, et al. Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma. World J Gastroenterol 2006; 12:2563-2568.
47. Nakagawa H, Maeda S, Yoshida H, et al. Serum IL-6 levels and the risk for hepatocarcinogenesis in chronic hepatitis C patients: an analysis based on gender differences. Int J Cancer 2009; 125:2264-2269.